Elon Musk (Patrick Pleul/Pool via AP, Arquivo)
November 14, 2022 11:20 AM ESTUpdated 12:10 PM
Pharma
Marketing

Eli Lil­ly pulls mil­lions in Twit­ter ad­ver­tis­ing af­ter fake ac­count de­ba­cle — re­port

Beth Snyder Bulik

Senior Editor

Eli Lil­ly is pulling its mil­lions in ad spend­ing on Twit­ter af­ter last week’s fake posts de­ba­cle, ac­cord­ing to a news re­port.

When an im­poster …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Among phar­ma CEOs, the IRA now and the IRA lat­er get very dif­fer­ent re­ac­tions

Bris­tol My­ers restarts ra­dio­phar­ma­ceu­ti­cal Phase 3 tri­al, but de­lays read­out by one year

An­drew Left, short sell­er who cam­paigned against Valeant, is ac­cused of fraud by SEC

Up­dat­ed: With cost-cut­ting un­der­way, Bris­tol My­ers rais­es guid­ance, touts Phase 3 win and scraps an­oth­er

Eu­ro­pean drug reg­u­la­tor re­jects Alzheimer's drug Leqem­bi, cit­ing safe­ty con­cerns

sponsored

Crit­i­cal Junc­tures in Gene Ther­a­py Clin­i­cal Ma­te­r­i­al Man­u­fac­tur­ing: Where Do I Start? And Will It Work?

A service from the Financial Times